

# Michael O'dwyer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5350442/publications.pdf>

Version: 2024-02-01

114  
papers

4,555  
citations

218381

26  
h-index

110170

64  
g-index

118  
all docs

118  
docs citations

118  
times ranked

6816  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 2425-2437.	13.9	1,261
2	Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. <i>New England Journal of Medicine</i> , 2019, 380, 2104-2115.	13.9	684
3	Frontline Science: COVID-19 infection induces readily detectable morphologic and inflammation-related phenotypic changes in peripheral blood monocytes. <i>Journal of Leukocyte Biology</i> , 2021, 109, 13-22.	1.5	241
4	Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. <i>Blood</i> , 2010, 115, 3796-3800.	0.6	236
5	Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1582-1596.	5.1	141
6	MYC dysregulation in the progression of multiple myeloma. <i>Leukemia</i> , 2020, 34, 322-326.	3.3	108
7	Targeting Selectins and Their Ligands in Cancer. <i>Frontiers in Oncology</i> , 2016, 6, 93.	1.3	95
8	The cancer glycome: Carbohydrates as mediators of metastasis. <i>Blood Reviews</i> , 2015, 29, 269-279.	2.8	91
9	Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. <i>Blood Advances</i> , 2019, 3, 1799-1807.	2.5	90
10	European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. <i>Haematologica</i> , 2018, 103, 1772-1784.	1.7	86
11	Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1047.	2.2	77
12	Targeting the Pim kinases in multiple myeloma. <i>Blood Cancer Journal</i> , 2015, 5, e325-e325.	2.8	75
13	Cdc7 kinase – A new target for drug development. <i>European Journal of Cancer</i> , 2010, 46, 33-40.	1.3	74
14	Proteomic characterization of human multiple myeloma bone marrow extracellular matrix. <i>Leukemia</i> , 2017, 31, 2426-2434.	3.3	72
15	Interferon- $\gamma$ -induced apoptotic responses of Fanconi anemia group C hematopoietic progenitor cells involve caspase 8-dependent activation of caspase 3 family members. <i>Blood</i> , 2000, 96, 4204-4211.	0.6	64
16	CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide. <i>Haematologica</i> , 2022, 107, 437-445.	1.7	63
17	Role of double-stranded RNA-dependent protein kinase in mediating hypersensitivity of Fanconi anemia complementation group C cells to interferon $\gamma$ , tumor necrosis factor- $\alpha$ , and double-stranded RNA. <i>Blood</i> , 2001, 97, 1644-1652.	0.6	60
18	Mechanisms of Action of a Dual Cdc7/Cdk9 Kinase Inhibitor against Quiescent and Proliferating CLL Cells. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1624-1634.	1.9	47

#	ARTICLE	IF	CITATIONS
19	Generating natural killer cells for adoptive transfer: expanding horizons. <i>Cytotherapy</i> , 2021, 23, 559-566.	0.3	45
20	AKT as a therapeutic target in multiple myeloma. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 897-915.	1.5	44
21	Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia. <i>Blood</i> , 2022, 139, 1135-1146.	0.6	39
22	Sialyltransferase inhibition leads to inhibition of tumor cell interactions with E-selectin, VCAM1, and MADCAM1, and improves survival in a human multiple myeloma mouse model. <i>Haematologica</i> , 2020, 105, 457-467.	1.7	35
23	E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271. <i>Leukemia</i> , 2017, 31, 2642-2651.	3.3	31
24	Hypoxia Impairs NK Cell Cytotoxicity through SHP-1-Mediated Attenuation of STAT3 and ERK Signaling Pathways. <i>Journal of Immunology Research</i> , 2020, 2020, 1-14.	0.9	31
25	Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA). <i>Blood</i> , 2018, 132, LBA-2-LBA-2.	0.6	30
26	Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell-mediated tumor responses. <i>Blood Advances</i> , 2022, 6, 3352-3366.	2.5	30
27	Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma. <i>HemaSphere</i> , 2020, 4, e350.	1.2	29
28	Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia. <i>Blood</i> , 2019, 134, 1875-1875.	0.6	26
29	T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study. <i>Blood</i> , 2019, 134, 142-142.	0.6	25
30	The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma. <i>BMC Medical Research Methodology</i> , 2018, 18, 66.	1.4	24
31	Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2022, 9, e403-e414.	2.2	23
32	Drugging the unfolded protein response in acute leukemias. <i>Journal of Hematology and Oncology</i> , 2015, 8, 87.	6.9	22
33	Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 1568.	1.7	21
34	Neurotrophins and B-cell malignancies. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 41-56.	2.4	19
35	CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study. <i>Blood Advances</i> , 2019, 3, 1815-1825.	2.5	19
36	Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative, and Subgroup Analyses. <i>Blood</i> , 2018, 132, 331-331.	0.6	19

#	ARTICLE	IF	CITATIONS
37	Targeting AML through DR4 with a novel variant of rhTRAIL. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 2216-2231.	1.6	18
38	Feeder Cells at the Interface of Natural Killer Cell Activation, Expansion and Gene Editing. <i>Frontiers in Immunology</i> , 2022, 13, 802906.	2.2	18
39	Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models. <i>Cancers</i> , 2013, 5, 901-918.	1.7	16
40	Practical Considerations for the Management of Patients in the Tyrosine Kinase Inhibitor Era. <i>Seminars in Hematology</i> , 2009, 46, S16-S21.	1.8	15
41	Targeted Approaches to Inhibit Sialylation of Multiple Myeloma in the Bone Marrow Microenvironment. <i>Frontiers in Bioengineering and Biotechnology</i> , 2019, 7, 252.	2.0	15
42	The CD38 <sup>low</sup> natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 421-434.	2.0	15
43	The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis. <i>Cancers</i> , 2011, 3, 1329-1350.	1.7	14
44	A phase III trial to evaluate the efficacy of uproleselan (GMI-1271) with chemotherapy in patients with relapsed/refractory acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS7066-TPS7066.	0.8	14
45	Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071985417.	1.1	13
46	Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis. <i>Oncotarget</i> , 2021, 10, 1859263.	2.1	13
47	Potential of Anti-Myeloma Activity of Daratumumab with Combination of Cyclophosphamide, Lenalidomide or Bortezomib Via a Tumor Secretory Response That Greatly Augments Macrophage-Induced ADCP. <i>Blood</i> , 2016, 128, 2101-2101.	0.6	13
48	Molecular response to first line nilotinib in a patient with e19a2 BCR-ABL1 chronic myeloid leukemia. <i>Leukemia Research</i> , 2011, 35, e169-e170.	0.4	12
49	Nilotinib 300 mg BID as frontline treatment of CML: Prospective analysis of the Xpert BCR-ABL Monitor system and significance of 3-month molecular response. <i>Leukemia Research</i> , 2014, 38, 310-315.	0.4	12
50	The dual inhibitor of the phosphoinositide 3-kinase and PIM kinases, IBL202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment. <i>British Journal of Haematology</i> , 2018, 182, 654-669.	1.2	12
51	A High Through-Put Screen for Small Molecules Modulating MCM2 Phosphorylation Identifies Ryuvidine as an Inducer of the DNA Damage Response. <i>PLoS ONE</i> , 2014, 9, e98891.	1.1	11
52	Successful venetoclax salvage in the setting of refractory, dialysis-dependent multiple myeloma with t(11;14). <i>Haematologica</i> , 2020, 105, e141-e143.	1.7	11
53	Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant. <i>HemaSphere</i> , 2021, 5, e561.	1.2	11
54	CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an "Off the Shelf" Therapy for Multiple Myeloma. <i>HemaSphere</i> , 2021, 5, e596.	1.2	11

#	ARTICLE	IF	CITATIONS
55	GMI-1271 Improves Efficacy and Safety of Chemotherapy in R/R and Newly Diagnosed Older Patients with AML: Results of a Phase 1/2 Study. <i>Blood</i> , 2017, 130, 894-894.	0.6	9
56	GMI-1271, a novel E-selectin antagonist, combined with induction chemotherapy in elderly patients with untreated AML. <i>Journal of Clinical Oncology</i> , 2017, 35, 2560-2560.	0.8	8
57	Tc Buster Transposon Engineered CLL-1 CAR-NK Cells Efficiently Target Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 1725-1725.	0.6	8
58	Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG] Tj ETQq0 0 0 rgBT /Overlock 10 abbreviated frontline therapy with FCR in non-del(17p) CLL. <i>Leukemia and Lymphoma</i> , 2018, 59, 1338-1347.	0.6	7
59	Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2016, 128, 4383-4383.	0.6	7
60	High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan. <i>Blood</i> , 2019, 134, 2690-2690.	0.6	6
61	Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia In Chronic Phase: Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR-ABL RQ PCR. <i>Blood</i> , 2010, 116, 3427-3427.	0.6	6
62	Estimating the Relative Effectiveness of Treatments in Relapsed/Refractory Multiple Myeloma through a Systematic Review and Network Meta-Analysis. <i>Blood</i> , 2015, 126, 2103-2103.	0.6	6
63	A Cell Culture System That Mimics Chronic Lymphocytic Leukemia Cells Microenvironment for Drug Screening and Characterization. <i>Methods in Molecular Biology</i> , 2013, 986, 217-226.	0.4	5
64	A Phase I/II Study of GMI-1271, a Novel E-Selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Elderly Previously Untreated Acute Myeloid Leukemia; Results to Date. <i>Blood</i> , 2016, 128, 4049-4049.	0.6	5
65	GMI-1271, a novel E-selectin antagonist, in combination with chemotherapy in relapsed/refractory AML. <i>Journal of Clinical Oncology</i> , 2017, 35, 2520-2520.	0.8	5
66	New developments in the treatment of multiple myeloma &ndash;  clinical utility of daratumumab. <i>Biologics: Targets and Therapy</i> , 2017, Volume 11, 31-43.	3.0	4
67	IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment. <i>Blood Advances</i> , 2020, 4, 5093-5106.	2.5	4
68	Immune-based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies. <i>HemaSphere</i> , 2020, 4, e423.	1.2	4
69	Initial Evaluation of Novel Dual PIM/PI3K and Triple PIM/PI3K/mTOR Inhibitors in Multiple Myeloma. <i>Blood</i> , 2014, 124, 5713-5713.	0.6	4
70	E-Selectin Ligand Expression Increases with Progression of Myeloma and Induces Drug Resistance in a Murine Transplant Model, Which Is Overcome By the Glycomimetic E-Selectin Antagonist, GMI-1271. <i>Blood</i> , 2015, 126, 1805-1805.	0.6	4
71	A novel molecular assay using hybridisation probes and melt curve analysis for CALR exon 9 mutation detection in myeloproliferative neoplasms. <i>Journal of Clinical Pathology</i> , 2017, 70, 662-668.	1.0	2
72	A novel CD2 staining-based flow cytometric assay for assessment of natural killer cell cytotoxicity. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23519.	0.9	2

#	ARTICLE	IF	CITATIONS
73	Patient-Initiated Discontinuation of Tyrosine Kinase Inhibitor for Chronic Myeloid Leukemia. Case Reports in Hematology, 2020, 2020, 1-4.	0.3	2
74	The EHA Research Roadmap: Immune-based Therapies for Hematological Malignancies. HemaSphere, 2021, 5, e642.	1.2	2
75	CD38 <sup>low</sup> Natural Killer Cells Transiently Expressing CD16F158V m-RNA Potentiates the Therapeutic Activity of Daratumumab Against Multiple Myeloma with Minimal Effector NK Cell Fratricide. Blood, 2018, 132, 3199-3199.	0.6	2
76	Targeting CD38 <sup>high</sup> Acute Myeloid Leukaemia with "Affinity Optimized" Chimeric Antigen Receptor and Membrane Bound TRAIL Expressing Natural Killer Cells. Blood, 2019, 134, 5536-5536.	0.6	2
77	Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM). Blood, 2015, 126, 495-495.	0.6	2
78	A 13-Glycosylation Gene Signature in Multiple Myeloma Can Predicts Survival and Identifies Candidates for Targeted Therapy (GiMM13). Blood, 2016, 128, 4423-4423.	0.6	2
79	A Phase II Multi-Center Study of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma - Ctrial-IE (ICORG) 13-17 Study. Blood, 2016, 128, 2117-2117.	0.6	2
80	Platelets Preferentially Bind to Myeloma Cells Bearing Sialofucosylated Structures and Protect Them from Natural Killer Cell-Mediated Cytotoxicity. Blood, 2018, 132, 4453-4453.	0.6	2
81	Hypersialylation protects Myeloma cells from NK cell mediated killing and this can be overcome by targeted desialylation using a sialyltransferase inhibitor.. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e159-e160.	0.2	1
82	Mesenchymal Stromal Cell Sialylation Modulates Antitumor Immune Responses In Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e93-e94.	0.2	1
83	Biclonal lymphoproliferative disorders: another association with NOTCH1-mutated chronic lymphocytic leukaemias. Irish Journal of Medical Science, 2020, 190, 1087-1094.	0.8	1
84	Enhancing Delivery of Small Molecule and Cell Based Therapies for Ovarian Cancer Using Advanced Delivery Strategies. Advanced Therapeutics, 2020, 3, 2000144.	1.6	1
85	How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma. Clinical Hematology International, 2021, 3, 27.	0.7	1
86	MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM). Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S424-S425.	0.2	1
87	CD38 Specific Chimeric Antigen Receptor KHYG-1 Natural Killer Cells: A Potential "Off the Shelf" Therapy for Multiple Myeloma. Blood, 2018, 132, 3261-3261.	0.6	1
88	The BH3 Mimetic, ABT-737, Overcomes Stromal-Mediated Pro-Survival Signals and Synergizes with PHA-767491, a Dual Cdc7/CDK9 Inhibitor, In Acute Myeloid Leukaemia. Blood, 2010, 116, 1841-1841.	0.6	1
89	Concurrent Inhibition of Pim and Akt Pathways with Pim447 and Afuresertib Activates FOXO3a and Depletes c-Myc to Induce Synergistic Cell Death in Multiple Myeloma. Blood, 2015, 126, 3007-3007.	0.6	1
90	The Dual PIM/PI3-K Inhibitor Ibl-202 Overcomes Microenvironmental Mediated Resistance in Multiple Myeloma and Prevents PIM1 Induced CXCR4 Upregulation. Blood, 2015, 126, 5350-5350.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Minimal Residual Disease (MRD) Status in FCR-Treated CLL Patients at the End of Treatment Influences Progression Free Survival (PFS), Results of the Ctrial-IE (ICORG) 07-01/ CLL Ireland Study, with Mutational Analysis Providing Additional Insight. <i>Blood</i> , 2016, 128, 3237-3237.	0.6	1
92	Evaluation of minimal residual disease in relapsed/refractory multiple myeloma patients treated with venetoclax or placebo in combination with bortezomib and dexamethasone: BELLINI study analyses.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8547-8547.	0.8	1
93	A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2650-2650.	0.6	1
94	Hypersialylation Protects Multiple Myeloma Cells from NK Cell-Mediated Immunosurveillance and This Can be Overcome By Targeted Desialylation Using a Sialyltransferase Inhibitor. <i>Blood</i> , 2019, 134, 138-138.	0.6	1
95	Promising Preliminary Activity of Optimized Affinity, CD38 CAR NK Cells Generated Using a Non-Viral Engineering Approach in Gene Edited Cord Blood Derived NK Cells for the Treatment of Multiple Myeloma. <i>Blood</i> , 2021, 138, 4793-4793.	0.6	1
96	Venetoclax and Epigenetic Modifiers: Promising Novel Combinations for the Treatment of Multiple Myeloma. <i>Blood</i> , 2021, 138, 4703-4703.	0.6	1
97	Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16-Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment. <i>Blood</i> , 2021, 138, 2756-2756.	0.6	1
98	Time to response, duration of response, and patient-reported outcomes (PROs) with daratumumab (DARA) plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of the phase 3 MAIA study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8044-8044.	0.8	1
99	Phase 3 Study of Ibrutinib versus Chlorambucil in Patients ≥65 Years with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S45-S46.	0.2	0
100	Arresting Resistance: Multi-Drug Resistant Organisms in Autologous Stem Cell Transplant Recipients at an Irish Tertiary Referral Centre. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S333-S334.	0.2	0
101	Cutaneous hypereosinophilia secondary to a low-grade B-cell lymphoma. <i>International Journal of Dermatology</i> , 2019, 58, e146-e147.	0.5	0
102	Poster: MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S252.	0.2	0
103	Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) for Relapsed and Refractory Multiple Myeloma (RRMM): Results from a Pharmacoeconomic Evaluation. <i>Blood</i> , 2014, 124, 2649-2649.	0.6	0
104	Clinical Characteristics, Treatment and Outcomes for Patients with Myelodysplastic Syndromes and Chromosome 5q Abnormalities in the Republic of Ireland. <i>Blood</i> , 2015, 126, 5258-5258.	0.6	0
105	The Dual PI3/PIM-Kinase Inhibitor, Ibl-202, Is Highly Synergistic with Venetoclax Against CLL Cells, and TP53-Knock-out Cells, and Under Conditions That Mimic the Tumor Microenvironment. <i>Blood</i> , 2018, 132, 1870-1870.	0.6	0
106	Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study. <i>Blood</i> , 2018, 132, 3242-3242.	0.6	0
107	Inhibition of Sialylation Impairs Adhesion on Madcam-1 and E-Selectin and Sensitize Multiple Myeloma Cells to Bortezomib in a Xenograft Mouse Model. <i>Blood</i> , 2018, 132, 3204-3204.	0.6	0
108	OAB-001: Overall survival and progression-free survival by treatment duration with Daratumumab + Lenalidomide/Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S1.	0.2	0

#	ARTICLE	IF	CITATIONS
109	P-094: ABT-199 and epigenetic modifiers: promising novel combinations for the treatment of Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S90.	0.2	0
110	Examining the Usefulness of the Charlson Comorbidity Index to Predict Early Mortality in Patients with Acute Myeloid Leukaemia. <i>Blood</i> , 2021, 138, 1218-1218.	0.6	0
111	Single Cell Transcriptomics Revealed Molecular Alterations in AML Cell Clusters Relevant to Refractory Disease at Relapse. <i>Blood</i> , 2021, 138, 3316-3316.	0.6	0
112	Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial. <i>Blood</i> , 2021, 138, 1655-1655.	0.6	0
113	Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA. <i>Blood</i> , 2021, 138, 4095-4095.	0.6	0
114	941â€¦Stromal cell sialylation suppresses T cells in inflammatory tumour microenvironments: a new tumour stromal cell immune checkpoint?. , 2021, 9, A987-A987.		0